SIREN : 542072459
BIOFARMA is a French company founded 126 years ago, specialized in the sector Activités spécialisées, scientifiques et techniques diverses. Based in SURESNES (92150), this company of category GE shows in 2024 a revenue of 30.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 30 586 044 € | 44 759 571 € | 38 335 323 € | 37 400 819 € | 40 424 503 € | 38 526 650 € | 37 329 508 € |
| Net income | 36 529 313 € | 116 580 532 € | 42 710 726 € | 36 496 547 € | 38 773 909 € | 55 072 043 € | 40 729 216 € |
| EBITDA | 22 344 884 € | 37 388 660 € | 31 301 746 € | 30 136 453 € | 32 723 402 € | 30 037 167 € | 30 234 266 € |
| Net margin | 119.4% | 260.5% | 111.4% | 97.6% | 95.9% | 142.9% | 109.1% |
In 2024, BIOFARMA achieves revenue of 30.6 M€. Activity remains stable over the period (CAGR: -2.5%). Significant drop of -32% vs 2023. After deducting consumption (0 €), gross margin stands at 30.6 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 22.3 M€, representing 73.1% of revenue. Warning negative scissor effect: despite revenue change (-32%), EBITDA varies by -40%, reducing margin by 10.5 pts. This reflects costs rising faster than revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 36.5 M€, i.e. 119.4% of revenue. This profit can be retained or distributed to shareholders.
30 586 044 €
30 586 044 €
22 344 884 €
22 251 993 €
36 529 313 €
73.1%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 100%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.0 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 154.2% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
0.011%
99.511%
154.219%
0.003
In 2024, the debt ratio of BIOFARMA (0.01) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2024, the financial autonomy of BIOFARMA (99.5%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of BIOFARMA (0.00) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 6114.11. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 43.5x. Operating income very largely covers interest expenses: high safety margin.
6114.115
43.5
In 2024, the liquidity ratio of BIOFARMA (6114.11) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of BIOFARMA (43.5x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 73 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 100 days. Favorable situation: supplier credit is longer than customer credit by 27 days. Overall, WCR represents 2622 days of revenue, i.e. 222.8 M€ to permanently finance. Notable WCR improvement over the period (-51%), freeing up cash.
222 787 827 €
73 j
100 j
0 j
2622 j
Based on 98 transactions of similar company sales
(all years),
the value of BIOFARMA is estimated at
77 498 688 €
(range 17 878 845€ - 128 741 502€).
With an EBITDA of 22 344 884€, the sector multiple of 3.5x is applied.
The price/revenue ratio is 0.36x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 98 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare BIOFARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Activités spécialisées, scientifiques et techniques diverses
The revenue of BIOFARMA in 2024 is 30.6 M€.
Yes, BIOFARMA generated a net profit of 36.5 M€ in 2024.
The headquarters of BIOFARMA is located in SURESNES (92150), in the department Hauts-de-Seine.
The tax return of BIOFARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
BIOFARMA operates in the sector Activités spécialisées, scientifiques et techniques diverses (NAF code 74.90B). See the 'Sector positioning' section above to compare the company with its competitors.